By the time most people are told they need to worry about their bones, bone loss has often been underway for years, quietly progressing without symptoms or warning signs.
This delay has real consequences. Nearly half of women over age 50 will experience a fracture related to low bone mass (osteopenia), and fractures lead to more hospitalizations each year than breast cancer, heart attack, or stroke. Even more striking: for many women, bone density screening doesn’t begin until around age 65, by which time nearly 80% already have osteopenia or osteoporosis.
Sōlaria Biō was founded to challenge this late-stage approach and rethink proactive bone health from a more biologically aligned starting point.
Sōlaria Biō’s Founding Story
The Question That Started It All
At the company’s founding was a simple question: Why does bone care typically begin after damage is already underway?
Bone density doesn’t suddenly drop because of osteoporosis. It erodes gradually, often accelerating in midlife, especially for women navigating perimenopause and menopause. Yet early screening and intervention remain the exception, not the norm.
“Bone loss is a natural part of aging, but good solutions to protect our bones are severely lacking, especially for women who need them most. I saw this firsthand when my mother was diagnosed with osteopenia and felt she had no good options to protect her bones.” - Mark Charbonneau, VP of Research & Development
That question became a north star internally, and it shaped how we built Bōndia.
From the start, the goal wasn’t to replace existing bone treatments. It was to support bone health earlier, before loss accelerates and options become more limited.
A Different Take on Proactive Bone Health
Sōlaria Biō’s founding team was deeply interested in how everyday biology—particularly the biology shaped by what we eat—affects long-term health. Fruits and vegetables don’t just provide nutrients; they also carry naturally occurring microbes that interact with the human body in complex ways.
The Gut–Bone Axis: The Missing Link in Proactive Bone Health
As the team looked more closely at what drives bone loss, one connection stood out: the gut–bone axis.
Bone health is shaped by bone remodeling: the ongoing balance between building new bone and breaking down old bone. When that balance shifts toward breakdown, bone density gradually declines. This process is strongly influenced by inflammation and immune signaling, not just by how much calcium or vitamin D you consume.
During menopause, estrogen loss alters immune signaling in ways that can accelerate bone breakdown. Inflammation becomes a key driver of this shift. Studies have shown that higher inflammatory activity is linked to increased bone resorption, while approaches that reduce inflammation can help slow it. This helps explain why bone loss often accelerates during midlife, even before it shows up clearly on a scan.
The gut microbiome plays an important role in regulating inflammation and immune signaling throughout the body. When gut barrier function is compromised or microbial balance shifts, inflammatory signals can increase—affecting bone remodeling downstream. Certain probiotic microbes may help support this balance by improving gut barrier function and producing compounds that help regulate inflammation.
This insight reframed proactive bone health entirely. If gut biology helps shape inflammatory signals that influence bone remodeling—especially during the hormonal transitions of midlife—then supporting gut health earlier may help influence how bones age over time.
Why a Medical Food, Not Another Supplement
Sōlaria Biō didn’t set out to create a better supplement.
The supplement category, by design, isn’t built for managing chronic, progressive conditions. It doesn’t require clinical evidence. It isn’t structured around condition-specific biology.
Bone health deserves a higher standard.
Medical foods are formulated for the dietary management of specific conditions, guided by recognized scientific principles and used under medical supervision. That framework allowed Sōlaria Biō to build a solution grounded in evidence, not marketing language.
From Hypothesis to Clinical Proof
Sōlaria Biō launched Bōndia with gold-standard clinical data.
Bōndia was evaluated in a 12-month, randomized, double-blind, placebo-controlled clinical study of 286 early postmenopausal women. The results showed that it improved bone loss by 85% in the femoral neck for women with osteopenia.
In this clinical study, Bōndia was safe and well-tolerated, with no differences in adverse events between product and placebo groups. Participants also reported 80% fewer severe gastrointestinal symptoms versus placebo.
“Bone loss is a gradual and cumulative process. That’s why a long-term, randomized, controlled trial was non-negotiable for us. We needed to rule out placebo effects and gather strong evidence that Bōndia protects bone over time." - Mark Charbonneau, VP of Research & Development
Clinical proof ensured that our solution was grounded in outcomes people can trust.
Looking Ahead: What Comes Next
At its core, Sōlaria Biō is a biotech company focused on advancing bone health by unlocking the power of the plant microbiome. From the beginning, the team believed that addressing the biological drivers of bone loss (like inflammation and nutrient utilization) required a deeper understanding of how plant-derived microbes interact with human biology.
That vision came to life first with Bōndia, but bone health is only the beginning.
We’ve built one of the world’s largest libraries of plant-derived microbes to address underserved inflammatory conditions, from osteopenia to rheumatoid arthritis and beyond. Our AI-powered Microscape Technology™ is designed to quickly pinpoint and rigorously validate synergistic microbial combinations, and translate those findings into targeted, evidence-driven interventions aimed at managing chronic disease. The long-term goal is to bridge cutting-edge microbiome research with everyday human health, expanding what bone density can look like across the lifespan.
The founding belief remains unchanged: when we address biology earlier, with rigor and respect for the systems that shape health, we can change outcomes—not just treat consequences.
